- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07915973
Impacto 2.0: Mobile Smoking Cessation Across Texas
Impacto 2.0: Addressing Disparities in Smoking Cessation Access and Outcomes for Hispanic Adults Who Smoke in Texas
This is a preliminary efficacy trial that will examine whether Impacto 2.0 produces higher rates of biochemically verified smoking abstinence among Hispanic adults across Texas compared to the NCI quitSTART app. The primary objective is to evaluate the preliminary efficacy of Impacto 2.0 in reducing smoking, tobacco withdrawal, and craving. One hundred Hispanic adults who smoke will be recruited across Texas and followed remotely over an 8-week intervention period with a 3-month post-quit follow-up.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Impacto 2.0 is a culturally adapted, bilingual (English and Spanish) smartphone-based smoking cessation intervention designed for Hispanic adults who smoke and have elevated anxiety sensitivity. The intervention includes smoking cessation content, psychoeducation, coping skills, and exercises designed to reduce anxiety sensitivity.
Eligible participants will be randomly assigned in a 1:1 ratio to receive either Impacto 2.0 or the National Cancer Institute's quitSTART app. Participants in both conditions will receive study-provided nicotine replacement therapy and will use their assigned mobile application during an 8-week treatment period.
Participants will complete 4 weeks of pre-quit app engagement, with their quit day and nicotine replacement therapy start scheduled at Week 4, followed by 4 weeks of post-quit treatment. Study assessments will be completed at baseline, Week 4, Week 8, and Week 16. Smoking status will be assessed through self-report and remote biochemical verification using the CoVita iCOquit Smokerlyzer.
The primary outcome is biochemically verified 7-day point-prevalence smoking abstinence at Week 8. Secondary outcomes include smoking abstinence at Week 16 and changes in anxiety sensitivity, tobacco withdrawal, and craving.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Michael J Zvolensky, Ph.D.
- Telefonnummer: 713-743-8056
- E-mail: mjzvolen@Central.UH.EDU
Studiesteder
-
-
Texas
-
Houston, Texas, Forenede Stater, 77204
- RESTORE Laboratory: Research on Emotion, Substance Treatment Outcomes, Rehabilitation, and Empowerment
-
Kontakt:
- Angelica G. Duran, B.S
- Telefonnummer: 713-743-8056
- E-mail: agduran@cougarnet.uh.edu
-
Ledende efterforsker:
- Micheal J Zvolensky, Ph.D.
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Self-identifies as Hispanic/Latino/a
- Currently resides in Texas
- Age 18 years or older
- Currently smokes combustible cigarettes daily, biochemically verified by expired carbon monoxide >7 ppm using the CoVita iCOquit Smokerlyzer
- Meets criteria for elevated anxiety sensitivity (cut-off score of 5 on the Short Scale Anxiety Sensitivity Index)
- Motivated to quit smoking
- Able to provide informed consent
- Has daily access to an iPhone or Android smartphone
- Fluent in English or Spanish
Exclusion Criteria:
- Current use of vaping/e-cigarettes, cigars, cigarillos, pipes, cannabis products, or other nicotine/tobacco products in addition to combustible cigarettes
- Current participation in alcohol or drug-use treatment, including smoking-cessation treatment
- Current psychotherapy for anxiety or depression
- Concurrent use of medication for anxiety or depression
- Active suicidality (ideation, intent, and/or plan)
- Current psychosis
- Currently pregnant, nursing, or actively trying to conceive, including male participants who report that they or a partner are actively trying to conceive
- Myocardial infarction within the past 2 weeks
- Uncontrolled high blood pressure
- Participants with the ability to become pregnant must provide a negative urine pregnancy test before final eligibility/onboarding
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Impacto 2.0
Participants will use the Impacto 2.0 smartphone application for 8 weeks. |
A culturally adapted, bilingual smartphone-based smoking cessation intervention that provides psychoeducation targeting anxiety sensitivity reduction. The app includes four lessons per week across the 8-week intervention period and exercises targeting anxiety sensitivity. |
|
Aktiv komparator: quitSTART
Participants will use the National Cancer Institute's quitSTART smartphone application for 8 weeks. |
The National Cancer Institute's quitSTART smartphone smoking cessation application. The app provides tools to help users understand smoking patterns, track smoking habits and urges, and manage cravings. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Biochemically Verified 7-Day Point Prevalence Smoking Abstinence
Tidsramme: Week 8
|
Smoking abstinence will be assessed using self-reported 7-day point prevalence abstinence and biochemically verified using the CoVita iCOquit Smokerlyzer. An expired carbon monoxide level <7 ppm will indicate abstinence. |
Week 8
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Biochemically Verified 7-Day Point Prevalence Smoking Abstinence
Tidsramme: Week 16
|
Smoking abstinence will be assessed using self-reported 7-day point prevalence abstinence and biochemically verified using the CoVita iCOquit Smokerlyzer. An expired carbon monoxide level <7 ppm will indicate abstinence. |
Week 16
|
|
Tobacco Withdrawal
Tidsramme: Baseline, Week 4, Week 8, and Week 16
|
Tobacco withdrawal will be assessed using the Minnesota Nicotine Withdrawal Scale (MNWS). |
Baseline, Week 4, Week 8, and Week 16
|
|
Tobacco Craving
Tidsramme: Baseline, Week 4, Week 8, and Week 16
|
Tobacco craving will be assessed using the Questionnaire of Smoking Urges-Brief (QSU-B). |
Baseline, Week 4, Week 8, and Week 16
|
|
Anxiety Sensitivity
Tidsramme: Baseline, Week 4, Week 8, and Week 16
|
Anxiety sensitivity will be assessed using the Short Scale Anxiety Sensitivity Index (SSASI). |
Baseline, Week 4, Week 8, and Week 16
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- STUDY00006201
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
There is no plan to make individual participant data (IPD) available to other researchers.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .